(E)-4-(3,4-dimethoxy phenyl)-2-oxobut-3-enoic acid | 117379-58-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-4-(3,4-dimethoxy phenyl)-2-oxobut-3-enoic acid
• 英文别名: (E)-4-(3,4-dimethoxyphenyl)-2-oxobut-3-enoic acid；3-oxo-1t-(3.4-dimethoxy-phenyl)-buten-(1)-oic acid-(4)；3-Oxo-1t-(3.4-dimethoxy-phenyl)-buten-(1)-saeure-(4)；4-(3,4-Dimethoxyphenyl)-2-oxobut-3-enoic acid
• CAS: 117379-58-5；65152-30-9
• 化学式: C₁₂H₁₂O₅
• 分子量: 236.224
• InChiKey: SHUJCNYJGLPHKM-HWKANZROSA-N

物化性质

• 沸点：
  398.9±42.0 °C(Predicted)
• 密度：
  1.265±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-4-(3,4-dimethoxy phenyl)-2-oxobut-3-enoic acid 在 盐酸 、 (5R,7R)-7-fluoro-5-isopropyl-2-(perfluorophenyl)-6,7-dihydro-5H-pyrrolo[2,1c][1,2,4]triazol-2-ium tetrafluoroborate 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 4.08h， 生成 (R)-ethyl 4-(3,4-dimethoxyphenyl)-5-(furan-2-yl)-2,5-dioxopentanoate
  参考文献：
  名称：

  Highly Enantioselective Intermolecular Stetter Reactions of β-Aryl Acceptors: α-Ketoester Moiety as Handle for Activation and Synthetic Manipulations

  摘要：

  The use of beta,gamma-unsaturated-alpha-ketoesters in the intermolecular Stetter reaction furnishes 1,2,5-tricarbonyl compounds in high yield and excellent enantioselectivity. The alpha,delta-diketoesters generated using this methodology serve as useful synthetic building blocks via chemo- and diastereoselective transformations.

  DOI：

  10.1021/ol202040b
• 作为产物：
  描述：

  3,4-二甲氧基苯甲醛 在 硫酸 、 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 生成 (E)-4-(3,4-dimethoxy phenyl)-2-oxobut-3-enoic acid
  参考文献：
  名称：

  Synthesis of some substituted furan-2(5H)-ones and derived quinoxalinones as potential anti-microbial and anti-cancer agents

  摘要：

  In search for novel anti-cancer and anti-microbial agents with promising pharmacotoxicological profile, the synthesis of some substituted 4-halofuran-2(5H)-ones (8a-l, 9, 11) and derived halogenated quinoxalin-2(1H)-ones (12a-d) is described. Some of the halogenated furanones were readily oxidized to the corresponding 2-bromo-2-propenoic acids (13a-c) with hydrogen peroxide in alkaline medium. Twenty-two compounds were preliminary tested for their in vitro activity against three bacteria and one fungus and revealed encouraging activity. On the other hand, three compounds were screened as anti-cancer agents using cell line panel protocol and 22 compounds were subjected to cycline-dependent kinases (CDKs) inhibition screening program but were inactive.

  DOI：

  10.1007/s00044-010-9394-2

文献信息

• NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：US20150336920A1

  公开（公告）日：2015-11-26

  The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.

  本发明涉及一种新型化合物，一种药学上可接受的盐或其光学异构体，一种制备方法，以及一种包含其作为活性成分的用于预防或治疗病毒性疾病的制药组合物。本发明的新型化合物不仅细胞毒性低，而且对柯萨奇病毒、肠道病毒、回肠病毒、脊髓灰质炎病毒和鼻病毒等小RNA病毒具有出色的抗病毒活性，因此可以有效地用作预防或治疗儿童麻痹症、急性出血性结膜炎、病毒性脑膜炎、手足口病、水痘、甲型肝炎、肌炎、心肌炎、胰腺炎、糖尿病、流行性肌痛、脑炎、感冒、疱疹咽峡炎、口蹄疫、哮喘、慢性阻塞性肺病、肺炎、鼻窦炎或中耳炎的制药组合物。
• COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Korea Research Institute of Chemical Technology

  公开号：EP3882244A1

  公开（公告）日：2021-09-22

  The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.

  本发明涉及一种新型化合物、其药学上可接受的盐或光学异构体、其制备方法以及以其为活性成分的预防或治疗病毒性疾病的药物组合物。根据本发明的新型化合物不仅细胞毒性低，而且对柯萨奇病毒、肠道病毒、埃可病毒、脊髓灰质炎病毒和鼻病毒等皮卡病毒具有优异的抗病毒活性，因此可有效地用作预防或治疗婴儿麻痹等病毒性疾病的药物组合物、急性出血性结膜炎、病毒性脑膜炎、手足口病、水泡病、甲型肝炎、肌炎、心肌炎、胰腺炎、糖尿病、流行性肌痛、脑炎、感冒、疱疹、口蹄疫、哮喘、慢性阻塞性肺病、肺炎、鼻窦炎或中耳炎。
• NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Korea Research Institute of Chemical Technology

  公开号：EP2933254B1

  公开（公告）日：2021-01-20
• Enol-lactone Tautomers of β-Bromobenzylidenepyruvic Acids
  作者：Emma Dietz Stecher、Ann Clements

  DOI：10.1021/ja01631a051

  日期：1954.1
• Particle Mass Emission Rates from Current-Technology, Light-Duty Gasoline Vehicles
  作者：Richard E. Chase、Gary J. Duszkiewicz、Trescott E. Jensen、Desmonia Lewis、E. John Schlaps、Arnie T. Weibel、Steven Cadle、Patricia Mulawa

  DOI：10.1080/10473289.2000.10464138

  日期：2000.6

  Now that the U.S. Environmental Protection Agency has promulgated new National Ambient Air Quality Standards for PM2.5, work will begin on generating the data required to determine the sources of ambient PM2.5 and the magnitude of their contributions to air pollution. This paper summarizes the results of an Environmental Research Consortium program, carried out under the auspices of the U.S. Council for Automotive Research. The program focused on particulate matter (PM) emissions from representative, current-technology, light-duty gasoline vehicles produced by DaimlerChrysler Corp., Ford Motor Co., and General Motors Corp. The vehicles, for the most part taken from the manufacturer's certification and durability fleets, were dynamometer-tested using the three-phase Federal Test Procedure in the companies' laboratories. The test fleet was made up of a mixture of both low-mileage (2K-35K miles) and high-mileage (60K-150K miles) cars, vans, sport utility vehicles, and light trucks. For each vehicle tested, PM emissions were accumulated over 4 cold-start tests, which were run on successive days. PM emission rates from the entire fleet (22 vehicles total) averaged less than 2 mg/mile. All 18 vehicles tested using California Phase 2 reformulated gasoline had PM emission rates less than 2 mg/mile at both low and high mileages.